Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning

Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting Lo...

Full description

Saved in:
Bibliographic Details
Published inBMC infectious diseases Vol. 21; no. 1; pp. 700 - 15
Main Authors Vekaria, Bindu, Overton, Christopher, Wiśniowski, Arkadiusz, Ahmad, Shazaad, Aparicio-Castro, Andrea, Curran-Sebastian, Jacob, Eddleston, Jane, Hanley, Neil A, House, Thomas, Kim, Jihye, Olsen, Wendy, Pampaka, Maria, Pellis, Lorenzo, Ruiz, Diego Perez, Schofield, John, Shryane, Nick, Elliot, Mark J.
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.07.2021
BioMed Central
BMC
Subjects
Aged
Bias
Care and treatment
Clinical outcomes
Complexity
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - therapy
Critical care
Data Analysis
Data collection
England
England - epidemiology
Epidemics
Estimates
Failure times
Female
Hospital Bed Capacity
Hospital patients
Hospital Planning - methods
Hospital utilization
Humans
Infections
Infectious diseases
Intensive Care Units - statistics & numerical data
Length of stay
Length of Stay - statistics & numerical data
Male
Medical informatics
Methods
Middle Aged
Occupancy
Pandemics
Patients
Quarantine
Severe acute respiratory syndrome coronavirus 2
Statistics
Survival
Survival Analysis
Viral diseases
Weibull distribution
England
United Kingdom
United Kingdom > UK
COVID-19
England
Survival Analysis
Length of stay
Online AccessGet full text

Cover

Abstract Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data. On a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy. All methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days. Given the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist.
AbstractList Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data. On a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy. All methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days. Given the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist.
Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data.BACKGROUNDPredicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data.On a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy.METHODOn a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy.All methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days.RESULTSAll methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days.Given the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist.CONCLUSIONSGiven the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist.
Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data. On a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy. All methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days. Given the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist.
Abstract Background Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data. Method On a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy. Results All methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days. Conclusions Given the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist.
Background Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data. Method On a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy. Results All methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days. Conclusions Given the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist. Keywords: COVID-19, Length of stay, Survival Analysis, England
Background Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without unnecessarily restricting care for patients with other conditions. Here, we demonstrate the utility of three complementary methods for predicting LoS using UK national- and hospital-level data. Method On a national scale, relevant patients were identified from the COVID-19 Hospitalisation in England Surveillance System (CHESS) reports. An Accelerated Failure Time (AFT) survival model and a truncation corrected method (TC), both with underlying Weibull distributions, were fitted to the data to estimate LoS from hospital admission date to an outcome (death or discharge) and from hospital admission date to Intensive Care Unit (ICU) admission date. In a second approach we fit a multi-state (MS) survival model to data directly from the Manchester University NHS Foundation Trust (MFT). We develop a planning tool that uses LoS estimates from these models to predict bed occupancy. Results All methods produced similar overall estimates of LoS for overall hospital stay, given a patient is not admitted to ICU (8.4, 9.1 and 8.0 days for AFT, TC and MS, respectively). Estimates differ more significantly between the local and national level when considering ICU. National estimates for ICU LoS from AFT and TC were 12.4 and 13.4 days, whereas in local data the MS method produced estimates of 18.9 days. Conclusions Given the complexity and partiality of different data sources and the rapidly evolving nature of the COVID-19 pandemic, it is most appropriate to use multiple analysis methods on multiple datasets. The AFT method accounts for censored cases, but does not allow for simultaneous consideration of different outcomes. The TC method does not include censored cases, instead correcting for truncation in the data, but does consider these different outcomes. The MS method can model complex pathways to different outcomes whilst accounting for censoring, but cannot handle non-random case missingness. Overall, we conclude that data-driven modelling approaches of LoS using these methods is useful in epidemic planning and management, and should be considered for widespread adoption throughout healthcare systems internationally where similar data resources exist.
ArticleNumber 700
Audience Academic
Author Overton, Christopher
Curran-Sebastian, Jacob
Pampaka, Maria
Ahmad, Shazaad
Hanley, Neil A
Shryane, Nick
Ruiz, Diego Perez
Vekaria, Bindu
Eddleston, Jane
Pellis, Lorenzo
Olsen, Wendy
Schofield, John
Kim, Jihye
Elliot, Mark J.
Wiśniowski, Arkadiusz
Aparicio-Castro, Andrea
House, Thomas
Author_xml – sequence: 1
  givenname: Bindu
  orcidid: 0000-0001-6605-7956
  surname: Vekaria
  fullname: Vekaria, Bindu
– sequence: 2
  givenname: Christopher
  surname: Overton
  fullname: Overton, Christopher
– sequence: 3
  givenname: Arkadiusz
  surname: Wiśniowski
  fullname: Wiśniowski, Arkadiusz
– sequence: 4
  givenname: Shazaad
  surname: Ahmad
  fullname: Ahmad, Shazaad
– sequence: 5
  givenname: Andrea
  surname: Aparicio-Castro
  fullname: Aparicio-Castro, Andrea
– sequence: 6
  givenname: Jacob
  surname: Curran-Sebastian
  fullname: Curran-Sebastian, Jacob
– sequence: 7
  givenname: Jane
  surname: Eddleston
  fullname: Eddleston, Jane
– sequence: 8
  givenname: Neil A
  surname: Hanley
  fullname: Hanley, Neil A
– sequence: 9
  givenname: Thomas
  surname: House
  fullname: House, Thomas
– sequence: 10
  givenname: Jihye
  surname: Kim
  fullname: Kim, Jihye
– sequence: 11
  givenname: Wendy
  surname: Olsen
  fullname: Olsen, Wendy
– sequence: 12
  givenname: Maria
  surname: Pampaka
  fullname: Pampaka, Maria
– sequence: 13
  givenname: Lorenzo
  surname: Pellis
  fullname: Pellis, Lorenzo
– sequence: 14
  givenname: Diego Perez
  surname: Ruiz
  fullname: Ruiz, Diego Perez
– sequence: 15
  givenname: John
  surname: Schofield
  fullname: Schofield, John
– sequence: 16
  givenname: Nick
  surname: Shryane
  fullname: Shryane, Nick
– sequence: 17
  givenname: Mark J.
  surname: Elliot
  fullname: Elliot, Mark J.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34294037$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1rFDEUhgep2A_9A17IgDd6MXXyOYkXQtmqXSgs-FEvQyaTzGaZnaxJttp_79ndVrtFRIYwh-Q5b3Je3uPiYAyjLYrnqD5FSPA3CWHRyKrGqKo5aVDFHxVHiEKBCaEH9-rD4jilRV2jRmD5pDgkFEtak-ao-HYR0spnPZSDHfs8L4MrU9Y3pQuxnMyupucVkuVKZ2_HnN6W5zrrqov-2o7l0uZ56NIWhfVDx65cDXoc_dg_LR47PST77PZ_Unz98P7L5KK6nH2cTs4uK8MJypXlljS1ky2SlnZCYCc4Y7J2jcGiE8xSJF0nnWgNZcRAjQjhRDCYt9ONIyfFdKfbBb1Qq-iXOt6ooL3aboTYKx2zN4NVtCEtt4gwxAxt20YKxG3bYcYlldwY0Hq301qt26XtDEwc9bAnun8y-rnqw7UCUxmnGARe3QrE8H1tU1ZLn4wdwBMb1klhxhiq4TIG6MsH6CKs4whWAcUxhdfVzR-q1zCAH12Ae81GVJ3xBhMqMKdAnf6Fgq-zS28gM87D_l7D670GYLL9mXu9TklNP3_6f3Z2tc--uG_gb-fu4gaA2AEmhpSidcpA9rIPGz_9oFCtNslWu2QrSLbaJltxaMUPWu_U_9H0C2cN9eY
CitedBy_id crossref_primary_10_4103_jfmpc_jfmpc_2107_21
crossref_primary_10_1080_13696998_2022_2111935
crossref_primary_10_1371_journal_pone_0291237
crossref_primary_10_1109_TASE_2022_3224171
crossref_primary_10_1016_j_vaccine_2025_126735
crossref_primary_10_1186_s12913_024_11238_y
crossref_primary_10_1371_journal_pone_0264892
crossref_primary_10_1038_s41598_024_61233_w
crossref_primary_10_37689_acta_ape_2023AO01112
crossref_primary_10_3390_ijerph19042224
crossref_primary_10_29001_2073_8552_2022_37_4_38_45
crossref_primary_10_3390_healthcare10071201
crossref_primary_10_3390_healthcare13010047
crossref_primary_10_1136_bmjopen_2021_054859
crossref_primary_10_2478_sjph_2022_0027
crossref_primary_10_3390_nu14010153
crossref_primary_10_1007_s11739_023_03493_4
crossref_primary_10_1016_j_heliyon_2023_e13545
crossref_primary_10_1186_s12879_022_07870_w
crossref_primary_10_1111_rssa_12955
crossref_primary_10_1016_j_resmer_2023_101026
crossref_primary_10_1111_risa_14213
crossref_primary_10_1177_20503121211070366
crossref_primary_10_29001_2073_8552_2022_447
crossref_primary_10_2147_CEOR_S360741
crossref_primary_10_1016_j_imj_2024_100151
crossref_primary_10_3390_vaccines11121791
crossref_primary_10_1098_rsta_2021_0302
crossref_primary_10_1137_23M1548049
crossref_primary_10_1016_j_procs_2022_09_179
crossref_primary_10_1186_s12879_022_07971_6
crossref_primary_10_1016_j_jedc_2022_104594
crossref_primary_10_1186_s12962_023_00425_z
crossref_primary_10_20473_jn_v19i2_53973
crossref_primary_10_1007_s10198_023_01621_7
crossref_primary_10_1177_20552076231170493
crossref_primary_10_3390_jcm12206678
crossref_primary_10_1186_s12961_024_01283_8
crossref_primary_10_1016_j_ejor_2021_12_044
crossref_primary_10_1016_j_mlwa_2022_100365
crossref_primary_10_1371_journal_pcbi_1010406
crossref_primary_10_1287_inte_2022_1149
crossref_primary_10_1080_14760584_2024_2383343
crossref_primary_10_1016_j_annemergmed_2022_05_036
crossref_primary_10_3390_ijerph19138195
crossref_primary_10_3390_antibiotics11060789
crossref_primary_10_1016_j_compbiomed_2024_108121
crossref_primary_10_1016_j_epidem_2021_100505
crossref_primary_10_1016_j_epidem_2022_100547
crossref_primary_10_1371_journal_pone_0298604
crossref_primary_10_1186_s43046_023_00199_8
crossref_primary_10_3389_fpubh_2021_809877
crossref_primary_10_1007_s11695_022_06267_7
crossref_primary_10_1371_journal_pone_0274158
crossref_primary_10_1016_S2666_5247_22_00182_3
crossref_primary_10_4103_jehp_jehp_1576_22
crossref_primary_10_1371_journal_pone_0287397
crossref_primary_10_3390_life14101232
crossref_primary_10_1177_1471082X221124628
crossref_primary_10_1111_rssc_12593
crossref_primary_10_1016_j_orhc_2023_100409
crossref_primary_10_1038_s41598_023_32292_2
crossref_primary_10_4103_apjtm_apjtm_520_23
crossref_primary_10_3389_frai_2023_1290022
crossref_primary_10_2147_JMDH_S362625
crossref_primary_10_3390_jcm10245763
crossref_primary_10_1016_j_ijdrr_2023_103794
crossref_primary_10_1080_14760584_2023_2158816
crossref_primary_10_1136_bmj_2022_073153
crossref_primary_10_1007_s00520_022_07098_z
crossref_primary_10_1186_s12879_022_07935_w
crossref_primary_10_1038_s41467_024_47199_3
crossref_primary_10_1080_2050571X_2024_2430116
crossref_primary_10_15656_kjcg_2021_22_2_75
crossref_primary_10_1016_j_ajic_2022_04_015
crossref_primary_10_1371_journal_pone_0278429
crossref_primary_10_1002_hsr2_1329
crossref_primary_10_3390_jpm13010132
crossref_primary_10_1371_journal_pcbi_1012096
crossref_primary_10_4081_mrm_2022_856
crossref_primary_10_1098_rsif_2021_0896
crossref_primary_10_3389_frai_2023_1179226
crossref_primary_10_1080_20479700_2023_2217564
crossref_primary_10_1007_s10479_023_05320_7
crossref_primary_10_1016_j_ijso_2023_100620
crossref_primary_10_1093_inthealth_ihad008
crossref_primary_10_1016_j_scitotenv_2023_162149
crossref_primary_10_1097_CCE_0000000000000912
crossref_primary_10_1186_s41182_022_00491_8
crossref_primary_10_1080_01605682_2024_2406230
crossref_primary_10_2196_47441
crossref_primary_10_1093_eurpub_ckac059
crossref_primary_10_3390_diagnostics13101760
crossref_primary_10_1186_s12874_023_01842_7
Cites_doi 10.1002/sim.7448
10.1101/2020.03.16.20036939
10.1191/0962280202sm281ra
10.1101/2020.04.12.20059972
10.1101/2020.03.26.20044842
10.1007/978-1-4899-3115-3
10.1111/j.2517-6161.1972.tb00899.x
10.1038/s41586-020-2521-4
10.1111/1467-9868.00177
10.1191/0962280202SM276ra
10.1002/sim.4780111409
10.1109/TR.2005.858093
10.1007/s10742-007-0020-9
10.1016/S0197-2456(03)00072-2
10.23889/ijpds.v5i4.1411
10.1017/CBO9780511802843
10.1136/bmj.m1328
10.1186/s12916-020-01726-3
10.1136/bmj.m1567
10.1201/9781315116945
10.1098/rstb.2020.0264
10.1093/jtm/taaa021
10.2307/2533008
10.1136/bmj.m308
10.7326/M20-1260
ContentType Journal Article
Copyright 2021. The Author(s).
COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: 2021. The Author(s).
– notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QL
7T2
7U9
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12879-021-06371-6
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE




Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Statistics
EISSN 1471-2334
EndPage 15
ExternalDocumentID oai_doaj_org_article_473b6e13515c4bb79816ebd2569496cc
PMC8295642
A672348264
34294037
10_1186_s12879_021_06371_6
Genre Journal Article
GeographicLocations England
United Kingdom
United Kingdom--UK
GeographicLocations_xml – name: England
– name: United Kingdom
– name: United Kingdom--UK
GrantInformation_xml – fundername: Royal Society
  grantid: INF/R2/180067
– fundername: Medical Research Council
  grantid: MR/R502236/1
– fundername: Medical Research Council
  grantid: MR/V038613/1
– fundername: Royal Society
  grantid: 202562/Z/16/Z
– fundername: ;
  grantid: INF/R2/180067
– fundername: ;
  grantid: MR/R502236/1
– fundername: ;
  grantid: 202562/Z/16/Z
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IOV
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7QL
7T2
7U9
7XB
8FK
AZQEC
C1K
COVID
DWQXO
H94
K9.
M7N
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c631t-e6e370f9b19e4d882f865590f7c28d85e419fd9f8bc453c9fd1336385637da7f3
IEDL.DBID M48
ISSN 1471-2334
IngestDate Wed Aug 27 01:29:06 EDT 2025
Thu Aug 21 13:17:10 EDT 2025
Fri Jul 11 06:51:55 EDT 2025
Fri Jul 25 02:54:34 EDT 2025
Tue Jun 17 21:29:51 EDT 2025
Tue Jun 10 20:35:26 EDT 2025
Fri Jun 27 03:50:01 EDT 2025
Fri Jun 27 03:46:30 EDT 2025
Mon Jul 21 06:03:04 EDT 2025
Tue Jul 01 01:57:50 EDT 2025
Thu Apr 24 22:52:41 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
England
Survival Analysis
Length of stay
Language English
License 2021. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c631t-e6e370f9b19e4d882f865590f7c28d85e419fd9f8bc453c9fd1336385637da7f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6605-7956
OpenAccessLink https://www.proquest.com/docview/2562479807?pq-origsite=%requestingapplication%
PMID 34294037
PQID 2562479807
PQPubID 42582
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_473b6e13515c4bb79816ebd2569496cc
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8295642
proquest_miscellaneous_2555104965
proquest_journals_2562479807
gale_infotracmisc_A672348264
gale_infotracacademiconefile_A672348264
gale_incontextgauss_ISR_A672348264
gale_incontextgauss_IOV_A672348264
pubmed_primary_34294037
crossref_citationtrail_10_1186_s12879_021_06371_6
crossref_primary_10_1186_s12879_021_06371_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-22
PublicationDateYYYYMMDD 2021-07-22
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-22
  day: 22
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC infectious diseases
PublicationTitleAlternate BMC Infect Dis
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References K Bogaerts (6371_CR23) 2017
EJ Williamson (6371_CR27) 2020; 584
6371_CR31
6371_CR11
KJ Carroll (6371_CR20) 2003; 24
6371_CR9
PK Andersen (6371_CR25) 2002; 11
JD Kalbfleisch (6371_CR18) 2011
6371_CR7
GE Weissman (6371_CR10) 2020; 173
J Kalbfleisch (6371_CR13) 1991; 1
L Pellis (6371_CR2) 2021; 376
L-J Wei (6371_CR17) 1992; 11
M Plummer (6371_CR21) 2003
6371_CR28
EM Rees (6371_CR8) 2020; 18
6371_CR29
6371_CR5
6371_CR6
MJ Crowther (6371_CR19) 2017; 36
6371_CR3
6371_CR4
6371_CR1
D Collett (6371_CR30) 1994
PK Andersen (6371_CR24) 2002; 11
J Sun (6371_CR14) 1995; 51
DR Cox (6371_CR16) 1972; 34
AC Davison (6371_CR26) 1997
NG Becker (6371_CR15) 1999; 61
C Sá (6371_CR12) 2007; 7
MP Kaminskiy (6371_CR22) 2005; 54
References_xml – volume: 36
  start-page: 4719
  issue: 29
  year: 2017
  ident: 6371_CR19
  publication-title: Stat Med
  doi: 10.1002/sim.7448
– ident: 6371_CR11
  doi: 10.1101/2020.03.16.20036939
– volume: 11
  start-page: 203
  issue: 2
  year: 2002
  ident: 6371_CR24
  publication-title: Stat Methods Med Res
  doi: 10.1191/0962280202sm281ra
– ident: 6371_CR7
  doi: 10.1101/2020.04.12.20059972
– volume-title: Proceedings of the 3rd International Workshop on Distributed Statistical Computing, vol. 124
  year: 2003
  ident: 6371_CR21
– ident: 6371_CR6
– ident: 6371_CR9
  doi: 10.1101/2020.03.26.20044842
– volume-title: Modelling Survival Data in Medical Research
  year: 1994
  ident: 6371_CR30
  doi: 10.1007/978-1-4899-3115-3
– volume: 34
  start-page: 187
  issue: 2
  year: 1972
  ident: 6371_CR16
  publication-title: J R Stat Soc Ser B (Methodol)
  doi: 10.1111/j.2517-6161.1972.tb00899.x
– volume: 584
  start-page: 430
  year: 2020
  ident: 6371_CR27
  publication-title: Nature
  doi: 10.1038/s41586-020-2521-4
– volume: 61
  start-page: 287
  issue: 2
  year: 1999
  ident: 6371_CR15
  publication-title: J R Stat Soc Ser B (Stat Methodol)
  doi: 10.1111/1467-9868.00177
– volume: 11
  start-page: 91
  issue: 2
  year: 2002
  ident: 6371_CR25
  publication-title: Stat Methods Med Res
  doi: 10.1191/0962280202SM276ra
– volume: 11
  start-page: 1871
  issue: 14-15
  year: 1992
  ident: 6371_CR17
  publication-title: Stat Med
  doi: 10.1002/sim.4780111409
– volume: 54
  start-page: 612
  issue: 4
  year: 2005
  ident: 6371_CR22
  publication-title: IEEE Trans Reliab
  doi: 10.1109/TR.2005.858093
– volume: 7
  start-page: 109
  issue: 3-4
  year: 2007
  ident: 6371_CR12
  publication-title: Health Serv Outcome Res Methodol
  doi: 10.1007/s10742-007-0020-9
– volume: 24
  start-page: 682
  issue: 6
  year: 2003
  ident: 6371_CR20
  publication-title: Control Clin Trials
  doi: 10.1016/S0197-2456(03)00072-2
– ident: 6371_CR28
  doi: 10.23889/ijpds.v5i4.1411
– ident: 6371_CR1
– volume-title: Bootstrap Methods and Their Application. Cambridge Series in Statistical and Probabilistic Mathematics
  year: 1997
  ident: 6371_CR26
  doi: 10.1017/CBO9780511802843
– ident: 6371_CR29
  doi: 10.1136/bmj.m1328
– volume: 18
  start-page: 1
  issue: 1
  year: 2020
  ident: 6371_CR8
  publication-title: BMC Med
  doi: 10.1186/s12916-020-01726-3
– ident: 6371_CR5
  doi: 10.1136/bmj.m1567
– volume-title: Survival Analysis with Interval-censored Data: A Practical Approach with Examples in R, SAS, and BUGS
  year: 2017
  ident: 6371_CR23
  doi: 10.1201/9781315116945
– ident: 6371_CR31
– volume: 376
  start-page: 20200264
  issue: 1829
  year: 2021
  ident: 6371_CR2
  publication-title: Philos Trans R Soc B Biol Sci
  doi: 10.1098/rstb.2020.0264
– ident: 6371_CR3
  doi: 10.1093/jtm/taaa021
– volume: 1
  start-page: 19
  issue: 1
  year: 1991
  ident: 6371_CR13
  publication-title: Stat Sin
– volume: 51
  start-page: 1096
  issue: 3
  year: 1995
  ident: 6371_CR14
  publication-title: Biometrics
  doi: 10.2307/2533008
– ident: 6371_CR4
  doi: 10.1136/bmj.m308
– volume: 173
  start-page: 21
  issue: 1
  year: 2020
  ident: 6371_CR10
  publication-title: Ann Intern Med
  doi: 10.7326/M20-1260
– volume-title: The Statistical Analysis of Failure Time Data, vol. 360
  year: 2011
  ident: 6371_CR18
SSID ssj0017829
Score 2.6017208
Snippet Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided without...
Background Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be provided...
Abstract Background Predicting hospital length of stay (LoS) for patients with COVID-19 infection is essential to ensure that adequate bed capacity can be...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 700
SubjectTerms Aged
Bias
Care and treatment
Clinical outcomes
Complexity
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - therapy
Critical care
Data Analysis
Data collection
England
England - epidemiology
Epidemics
Estimates
Failure times
Female
Hospital Bed Capacity
Hospital patients
Hospital Planning - methods
Hospital utilization
Humans
Infections
Infectious diseases
Intensive Care Units - statistics & numerical data
Length of stay
Length of Stay - statistics & numerical data
Male
Medical informatics
Methods
Middle Aged
Occupancy
Pandemics
Patients
Quarantine
Severe acute respiratory syndrome coronavirus 2
Statistics
Survival
Survival Analysis
Viral diseases
Weibull distribution
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojxDS2UQEgdkNQ8_ufVB1SKVSkBLb1bs2LRSla2a7IF_z0zirDZCwIVDpFU8lrxfZjwzyfgbQt5K7PsIlsR0VIbxJgRWQxTChgQk1No1EV_on36Wx-f806W4XGv1hTVhIz3wCNwuV5WTAfvICc-dU0YXMrgGPLXhRnqPuy_4vCmZSt8PwO-Z6YiMlrsd7MKwFCxHAJesCiZnbmhg6_99T15zSvOCyTUPdPSIPEyhI90bl7xJ7oX2Mbl_mj6OPyHfpx4gFLuj9Fd0ESnEfj8pxKX04Ozi5JAVhiYi1e4DPaz7mjV3uN3RsZF0N4jChaW09Db1M3pKzo8-fjs4ZqlvAvOyKnoWZKhUHo0rTOANhNART5-aPCpf6kaLwAsTGxO181xUHn5Dogp2KACaplaxekY22kUbXhAq8sKhC1e19hyyaIf5TxR1I7TUvjQZKSYYrU-k4tjb4sYOyYWWdoTeAvR2gN7KjLxfzbkdKTX-Kr2PT2cliXTYww1QEpuUxP5LSTLyBp-tRcKLFitqftTLrrMnZxd2T6oSCX4k_5PQ1y8zoXdJKC7gj_o6nWIAuJBIaya5PZMEs_Xz4UnPbNo2OgsLLjmsPlcZeb0axplYCteGxRJlIMjNkeY_I89HtVyBU0F0wfMKZquZws7Qm4-011cDqTgYjIBc9OX_gHuLPCgHW1OsLLfJRn-3DK8gduvdzmCmvwATMTtf
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86QXwRv1edEkXwQcL6kebDF5mbYxPmQN28b6FJk02Q9nrb--B_7zltel0R91AozQm0J-czPfkdQl4L7PsImsRUkJrx2ntWQRTChgTEV8rWATf0Tz6LozP-aVEu4oZbF8sqJ5s4GOq6dbhHvguuOedSq1S-X_5i2DUK_67GFho3yS2ELsOSLrnYJFwZeD89HZRRYrcDWwwvhEUJ4JhlxsTMGQ2Y_f9a5iuuaV42ecUPHd4jd2MASffGFb9PbvjmAbl9En-RPyTfp04gFHuk9Je0DRQiwN8UolO6f3p-fMAyTSOcaveOHlR9xeoVGj06tpPuBlK4sKCWLmNXo0fk7PDjt_0jFrsnMCeKrGde-EKmQdtMe15DIB3wDKpOg3S5qlXpeaZDrYOyjpeFg3tIV0EbS2BNXclQPCZbTdv4bULLNLPoyGWlHIdc2mIWFMqqLpVQLtcJySY2GhehxbHDxU8zpBhKmJH1BlhvBtYbkZC3mznLEVjjWuoPuDobSgTFHh60qwsTdcxwWVjhseVg6bi1ICyZ8LYGydFcC-cS8grX1iDsRYN1NRfVuuvM8em52RMyR5gfwf9H9PXLjOhNJAotfKir4lkGYBfCac0od2aUoLxuPjzJmYnGozN_RT0hLzfDOBML4hrfrpEGQt0Uwf4T8mQUyw1zCogxeFrAbDkT2Bn35iPNj8sBWhwUpoSM9On1r_WM3MkHLZIsz3fIVr9a--cQm_X2xaCAfwCxkzOC
  priority: 102
  providerName: ProQuest
Title Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning
URI https://www.ncbi.nlm.nih.gov/pubmed/34294037
https://www.proquest.com/docview/2562479807
https://www.proquest.com/docview/2555104965
https://pubmed.ncbi.nlm.nih.gov/PMC8295642
https://doaj.org/article/473b6e13515c4bb79816ebd2569496cc
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3rb9MwELf2kNC-IBivwqgMQuIDCuTh-IGE0Npt2pC6oUJHtS9W4tgb0pSOppXYf8-dk5RFjH1oVNXn1j3757tLzvcj5A1H3kdAUiCdUAErrA0y8EICH4DYTOaFwxv6o2N-OGFfpul0jbR0R40Cq1tDO-STmswv3__-df0ZAP_JA17yDxXssfBDmGwABldEAV8nm2CZBAJ1xP4-VQBrqPxpI5CJk4S1h2hu_Y6OofL1_P_dtW-YrW5K5Q0bdfCA3G-cS7pbr4aHZM2W2-TeqHl8vk220LWsKzM_Ij9ayhCKZCqLCzpzFFzFawpuLB2enB7tBZGiTd3V6iPdyxZZUMxxd6Q173TlReGFmbf0qqE_ekwmB_vfh4dBQ7MQGJ5Ei8Bym4jQqTxSlhXgcTs8rKpCJ0wsC5laFilXKCdzw9LEwHuIawG2KeipyIRLnpCNclbaZ4SmYZSjxReZNAyC7hzDJZdmRSq5NLHqkajVqTZNDXKkwrjUPhaRXNfzoGEetJ8HzXvk3arPVV2B407pAU7VShKrZ_sPZvNz3YBRM5Hk3CI3YWpYngslI27zArw_xRQ3pkde40RrrI9RYgLOebasKn10cqp3uYixHhBn_xP6Nu4IvW2E3Az-qMmaQw-gLqy71ZHc6UgCyk23uV10ugWJhgHHDEYfih55tWrGnpg5V9rZEmXAJw6RFaBHntZrdKWcBJwRFibQW3RWb0d73Zby54WvQQ5ISiF0fX73qF-QrdhDSgRxvEM2FvOlfQlO3CLvk3UxFXCVw6hPNgf7x1_HfX9DpO8xC9fx4OwPXxNByw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF6VIgEviJtAgQWBeECr-ljvgYRQaagS2rQStCVvi73ebZGQHeJEqH-K38iMj1AL0bc-RIqy4yiZneMbe3Y-Ql4K5H0ET2LKS8147hxLAYWwugBxqcpyjzf0J_tidMQ_TZPpGvndnYXBtsouJtaBOi8t3iPfhNQccalVIN_PfjJkjcKnqx2FRmMWu-7sF5Rs1bvxEPb3VRTtfDzcHrGWVYBZEYcL5oSLZeB1FmrHcwCYHs9m6sBLG6lcJY6H2ufaq8zyJLbwHso4sNJExDJPpY_he6-Qq5B4A_QoOV0VeCFkW90dzFFis4LYDwrAJggAAjJkopf8ao6AfzPBuVTYb9M8l_d2bpGbLWClW42F3SZrrrhDrk3aR_J3ydeOeYQiJ8vilJaeAuI8o4CG6fbB8XjIQk3b8a3VWzpMFynL5xhkaUNfXdWi8MIGXjprWZTukaNL0et9sl6UhXtIaBKEGQIHmSrLoXbPsOrySZonSigb6QEJOzUa244yR0aNH6YuaZQwjeoNqN7UqjdiQN6srpk1gzwulP6Au7OSxCHc9Qfl_MS0Pm24jDPhkOIwsTzLwDhD4bIcLFVzLawdkBe4twbHbBTYx3OSLqvKjA-OzZaQEY4VEvx_Ql8-94Ret0K-hD9q0_bsBKgLx3f1JDd6khAsbH-5szPTBqvK_HWtAXm-WsYrsQGvcOUSZQBaB0guMCAPGrNcKScGTMODGK6WPYPtaa-_Unw_rUeZg8MkUAE_uvhnPSPXR4eTPbM33t99TG5EtUdJFkUbZH0xX7ongAsX2dPaGSn5dtne_wfGSW_T
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hospital+length+of+stay+for+COVID-19+patients%3A+Data-driven+methods+for+forward+planning&rft.jtitle=BMC+infectious+diseases&rft.au=Vekaria%2C+Bindu&rft.au=Overton%2C+Christopher&rft.au=Wi%C3%85niowski%2C+Arkadiusz&rft.au=Ahmad%2C+Shazaad&rft.date=2021-07-22&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-021-06371-6&rft.externalDocID=A672348264
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon